DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación
Artículo científico (JournalArticle)
Allosteric modulation of the CXCR4:CXCL12 axis by targeting receptor nanoclustering via the TMV-TMVI domain
CXCR4 is a ubiquitously expressed chemokine receptor that regulates leukocyte trafficking and arrest in both homeostatic and pathological states. It also participates in organogenesis, HIV-1 infection, and tumor development. Despite the potential therapeutic benefit of CXCR4 antagonists, only one, plerixafor (AMD3100), which blocks the ligand-binding site, has reached the clinic. Recent advances in imaging and biophysical techniques have provided a richer understanding of the membrane organization and dynamics of this receptor. Activation of CXCR4 by CXCL12 reduces the number of CXCR4 monomers/dimers at the cell membrane and increases the formation of large nanoclusters, which are largely immobile and are required for correct cell orientation to chemoattractant gradients. Mechanistically, CXCR4 activation involves a structural motif defined by residues in TMV and TMVI. Using this structural motif as a template, we performed in silico molecular modeling followed by in vitro screening of a small compound library to identify negative allosteric modulators of CXCR4 that do not affect CXCL12 binding. We identified AGR1.137, a small molecule that abolishes CXCL12-mediated receptor nanoclustering and dynamics and blocks the ability of cells to sense CXCL12 gradients both in vitro and in vivo while preserving ligand binding and receptor internalization., This work was supported by grants from the Spanish Ministry of Science and Innovation (PID2020-114980RB-I00) Agencia Estatal de Investigación/Fondo Europeo de Desarrollo Regional (AEI/FEDER), Unión Europea, and by a grant from the Regional Government of Madrid P2022/BMD- 7274. CS is supported by MCIN /AEI /10.13039/501100011033/FEDER, UE (PID2022- 140651NB- I00). NEC is supported by a grant of the Spanish Ministry of Economy, Industry and Competitivity (RTI2018-096100B-100). RJS is supported by FSE/FEDER through the Instituto de Salud Carlos III (ISCIII; CP20/00043). EG- C was supported by the program Apoyos Centros de Excelencia S.O. of the Spanish Ministry of Science and Innovation (SEV- 2017- 0712). PM and SG are included in the doctoral program
of the Department of Molecular Biosciences, Universidad Autónoma de Madrid, and are supported by the Fondo de Personal Investigador (FPI) program of the Spanish Ministry for Science and Innovation (BES2015- 071302 and PRE2018- 083201 respectively). RA- B is supported by the Garantía Juvenil program of the Regional Government of Madrid, Spain (CAM20_CNB_AI_07). We also acknowledge the technical help of the Advance Light Microscopy Unit at the CNB/CSIC. Compounds AGR1.31, AGR1.35 and AGR1.37 are included in the patent PCT/ES2022/070379., Peer reviewed
Proyecto:
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2017-2020 PID2020-114980RB-I00
,
AEI / Plan Estatal de Investigación Científica y Técnica y de Innovación 2021-2023 PID2022-140651NB-I00
DOI: http://hdl.handle.net/10261/373662, https://api.elsevier.com/content/abstract/scopus_id/85203768304
HANDLE: http://hdl.handle.net/10261/373662, https://api.elsevier.com/content/abstract/scopus_id/85203768304